Maternal & Neonatal Health drugs

28 results

  • albuked

    (Albumin (Human))
    KEDRION BIOPHARMA, INC.
    Albuked 25 is indicated for emergency treatment of hypovolemic shock, burn therapy, and as a treatment for hypoproteinemia, ARDS, acute liver failure, neonatal hemolytic disease, and acute nephrosis. It may also be used during cardiopulmonary bypass and renal dialysis to maintain blood volume and colloid osmotic pressure.

  • annovera

    (segesterone acetate and ethinyl estradiol)
    TherapeuticsMD, Inc.
    ANNOVERA is indicated for females of reproductive potential to prevent pregnancy. It is not adequately studied in females with a BMI greater than 29 kg/m².

  • bijuva

    (estradiol and progesterone)
    Mayne Pharma LLC
    The drug is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause.

  • bonjesta

    (doxylamine succinate and pyridoxine hydrochloride)
    Duchesnay USA, Inc.
    BONJESTA is indicated for treating nausea and vomiting of pregnancy in women unresponsive to conservative measures. It has not been studied for hyperemesis gravidarum.

  • botox

    (onabotulinumtoxinA)
    Allergan, Inc.
    BOTOX is indicated for treating overactive bladder, neurogenic detrusor overactivity in pediatric patients, chronic migraine prophylaxis, spasticity, cervical dystonia, severe primary axillary hyperhidrosis, and blepharospasm/strabismus associated with dystonia in patients aged 12 and older. It is meant for those unresponsive or intolerant to anticholinergic medications.

  • diclegis

    (doxylamine succinate and pyridoxine hydrochloride)
    Duchesnay USA, Inc.
    DICLEGIS is indicated for the treatment of nausea and vomiting of pregnancy in women who have not responded to conservative management. It has not been studied in cases of hyperemesis gravidarum.

  • hemangeol

    (propranolol hydrochloride)
    Pierre Fabre Pharmaceuticals, Inc.
    HEMANGEOL oral solution, containing propranolol hydrochloride, is indicated for the treatment of proliferating infantile hemangioma that requires systemic therapy.

  • kyleena

    (Levonorgestrel)
    Bayer HealthCare Pharmaceuticals Inc.
    Kyleena is indicated for the prevention of pregnancy for up to 5 years. If continued use is desired, the device should be replaced after 5 years.

  • liletta

    (Levonorgestrel)
    Allergan, Inc.
    LILETTA is indicated for contraception to prevent pregnancy for up to 8 years and for the treatment of heavy menstrual bleeding for up to 5 years in patients using intrauterine contraception, with replacement required after 5 years if continued treatment is necessary.

  • lo loestrin fe

    (norethindrone acetate and ethinyl estradiol, ethinyl estradiol and ferrous fumarate)
    Allergan, Inc.
    Lo Loestrin® Fe is indicated for the prevention of pregnancy in women. Its efficacy in women with a BMI greater than 35 kg/m² has not been evaluated.